Dr Michael Atkins (MedStar Georgetown University Hospital, Washington, DC, USA) shares three areas for development to help improve the safe and effective use of immune checkpoint inhibitors.
1. Having a rational approach to stopping therapy (00:50-02:20)
2. An improved understanding of toxicity and response (02:20-04:25)
3. The role of combining and sequencing immunotherapy with standard treatment (04:30-06:05)
Speaker Disclosure: Michael Atkins is a member of the advisory board at: BMS, Merck, Novartis, Eisai, Aveo, Pfizer, Werewolf, Fathom, Pneuma, Leads, Pyxis Oncology, PACT, Elpis, X4Pharma, ValoHealth, ScholarRock, Surface, Takeda, Simcha, Roche and SAB Bio. He has been a consultant for: BMS, Merck, Novartis, Pfizer, Roche, Exelixis, Iovance, COTA, Idera, Agenus, Apexigen, Asher Bio, Neoleukin, AstraZeneca, Calithera, SeaGen and Sanofi. He has received research support to his institution from BMS, Merck, Pfizer, and has stock options at Werewolf, Pyxis Oncology and Elpis.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
